Skip to main content
. 2009 May;50(5):846–853. doi: 10.1194/jlr.M800428-JLR200

Fig. 3.

Fig. 3.

Immunoreactivity of DMPC-treated LDL to apoB MAbs. Increasing concentrations of human LDL were incubated with DMPC (1 mM) at 37°C for 2 h. A to E: The immunoreactivity of DMPC-treated LDL to human apoB monoclonal antibodies 1D1, MB47, 605, Bsol7, and 4H11 was monitored by an apoB-specific ELISA in triplicate. F: The immunoreactivity of DMPC-treated LDL with each monoclonal antibody was compared with control LDL at 275 μg/ml of LDL (*P < 0.01, **P < 0.001, and ***P < 0.0001, compared with control LDL).